Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 4/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.45 |
| ▸ | PIK3R1 | P27986 | 8/20 | 0.45 |
| ▸ | MTOR | P42345 | 5/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15079657 | 0.85 | FLT3 (0.57) | FLT3MTORNPC1TP53RAB9A | |
| SCHEMBL15079492 | 0.84 | FLT3 (0.49) | FLT3PIK3CAPIK3R1MTORNPC1 | |
| SCHEMBL15079472 | 0.75 | FLT3 (1.00) | FLT3 | |
| SCHEMBL75005 | 0.75 | RAB9A (0.48) | FLT3PIK3CAPIK3R1MTORNPC1 | |
| SCHEMBL75006 | 0.75 | SMN1; SMN2 (0.46) | FLT3PIK3CAPIK3R1MTORNPC1 | |
| SCHEMBL17706299 | 0.75 | FLT3 (0.67) | FLT3 | |
| SCHEMBL15079653 | 0.74 | FLT3 (0.57) | FLT3 | |
| SCHEMBL15079494 | 0.72 | FLT3 (0.64) | FLT3NPC1RAB9AALDH1A1ATR | |
| SCHEMBL3725617 | 0.70 | PIK3CA (0.72) | FLT3PIK3CAPIK3R1MTORPIK3CD | |
| SCHEMBL15079490 | 0.69 | MAPT (0.44) | FLT3NPC1TP53RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2763998-B1 | TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO LTD (CN) | 2016-04-27 | — | — | EP | disclosed |
| US-9216997-B2 | Tri-heterocyclic derivatives, preparation process and uses thereof | SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) | 2015-12-22 | — | — | US | disclosed |
| US-9216997-B2 | Tri-heterocyclic derivatives, preparation process and uses thereof | SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) | 2015-12-22 | — | — | US | disclosed |
| US-20140329800-A1 | TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) | 2014-11-06 | — | — | US | disclosed |
| US-20140329800-A1 | TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) | 2014-11-06 | — | — | US | disclosed |
| WO-2013091502-A1 | TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO LTD. (CN) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329800-A1 | TRI-HETEROCYCLIC DERIVATIVES, PREPARATION PROCESS AND USES THEREOF | MAP3K15, MAP3K1, MAP3K5 | FLT3 123/4885PIK3CA 104/4885PIK3R1 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.